Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) is a clinical-stage oncology therapeutics company developing antibody-drug conjugates (ADCs) for cancers. Its portfolio comprises three licensed candidates using the CPT113 linker-payload platform, which joins tumor-targeting antibodies to a topoisomerase I inhibitor:… From the company’s description.
Over the twelve months to Jun 30, 2026, Whitehawk Therapeutics, Inc. reported a net loss of $79.83M. Operations used $69.35M in cash. In fiscal 2025, it reported revenue of $7.14M, down 72.5% from fiscal 2024, and a net loss of $20.60M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Whitehawk Therapeutics, Inc. does
In the company’s own words
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) is a clinical-stage oncology therapeutics company developing antibody-drug conjugates (ADCs) for cancers. Its portfolio comprises three licensed candidates using the CPT113 linker-payload platform, which joins tumor-targeting antibodies to a topoisomerase I inhibitor: HWK-007 targets PTK7 and is being studied in solid tumors including lung and ovarian cancers; HWK-016 targets membrane-bound MUC16 for ovarian and endometrial cancers; and HWK-206 targets SEZ6 for small cell lung cancer and neuroendocrine tumors. Whitehawk holds worldwide development and commercialization rights to these candidates and relies on external partners for research, development and manufacturing. Its FDA-cleared Phase 1 trials for HWK-007 and HWK-016 are underway, while HWK-206 remains in preclinical development. The company previously developed and commercialized FYARRO for advanced malignant PEComa, but sold the operating business in March 2025. Whitehawk reported $7.1 million in FYARRO net product sales for 2025, before and during the divestiture year. Its website is www.whitehawktx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MORRISTOWN, NJ
- Fiscal year end
- December
- CIK
- 1422142
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Whitehawk Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Whitehawk Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Whitehawk Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Whitehawk Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Whitehawk Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”